Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Pichler

Showing results (291-300 of 306) with videos related to

Pageof 31
Sort By:
International Journal of Cancer|October 22, 2025
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysisDora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
Frontiers in Surgery|October 24, 2022
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patientsJohannes Mischinger, Helmut Schöllnast, Hanna Zurl, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Molecular Oncology|March 14, 2023
Disclosing quantitative RT-PCR raw data during manuscript submission: a call for actionAndreas Untergasser, Jan Hellemans, Michael W Pfaffl, et al.
Therapeutic Advances in Medical Oncology|April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based studyKlaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2019
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric StudyKlaus-Peter Dieckmann, Arlo Radtke, Lajos Geczi, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Genome Medicine|March 1, 2020
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumorsChristopher G Smith, Tina Moser, Florent Mouliere, et al.
Gut|March 26, 2015
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasisHui Ling, Karen Pickard, Cristina Ivan, et al.
Pageof 31

Showing results (291-300 of 306) with videos related to

Sort By:
Pageof 31
International Journal of Cancer|October 22, 2025
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysisDora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
Frontiers in Surgery|October 24, 2022
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patientsJohannes Mischinger, Helmut Schöllnast, Hanna Zurl, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Molecular Oncology|March 14, 2023
Disclosing quantitative RT-PCR raw data during manuscript submission: a call for actionAndreas Untergasser, Jan Hellemans, Michael W Pfaffl, et al.
Therapeutic Advances in Medical Oncology|April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based studyKlaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2019
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric StudyKlaus-Peter Dieckmann, Arlo Radtke, Lajos Geczi, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Genome Medicine|March 1, 2020
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumorsChristopher G Smith, Tina Moser, Florent Mouliere, et al.
Gut|March 26, 2015
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasisHui Ling, Karen Pickard, Cristina Ivan, et al.
Pageof 31